DOCSLIB.ORG

Annual Report 2016 Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Annual Report 2016 Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital Moving Annual report 2016 Department of Nuclear Medicine & PET-Centre, Aarhus University Hospital Department of Nuclear Medicine & PET-Centre 2016 Nørrebrogade Building 3, Nørrebrogade , Building 10 Skejby TABLE OF CONTENTS Table of contents Preface ............................................................................................................................................................................................................................................................................................................. 1 Organisation.................................................................................................................................................................................................................................................................................................. 3 Department adresses........................................................................................................................................................................................................................................................................ 3 Organisation chart .............................................................................................................................................................................................................................................................................. 3 Staff .............................................................................................................................................................................................................................................................................................................. 4 Equipment ...................................................................................................................................................................................................................................................................................................... 7 Excellence – from molecule to man ............................................................................................................................................................................................................................................... 8 Radiochemistry ............................................................................................................................................................................................................................................................................................ 9 Radiochemistry - PET ........................................................................................................................................................................................................................................................................ 9 Radiochemistry – Nuclear medicine..................................................................................................................................................................................................................................... 12 Neuroscience ............................................................................................................................................................................................................................................................................................ 14 Molecular imaging of brain disorders .................................................................................................................................................................................................................................. 14 Clinical nuclear medicine examinations in brain disorders ................................................................................................................................................................................... 14 Research in Parkinson’s disease.............................................................................................................................................................................................................................................. 16 Research in Alzheimer’s disease............................................................................................................................................................................................................................................. 17 Imaging glutamate ion channel activation ..................................................................................................................................................................................................................... 18 Research in REM sleep behavior disorder and prodromal Parkinson’s disease ........................................................................................................................................ 19 Nuclear cardiology ................................................................................................................................................................................................................................................................................ 21 Nuclear oncology ................................................................................................................................................................................................................................................................................... 23 PSMA PET/CT in prostate cancer ........................................................................................................................................................................................................................................... 23 Metabolism.................................................................................................................................................................................................................................................................................................. 25 Metabolism from a PET perspective ..................................................................................................................................................................................................................................... 25 Inflammation.............................................................................................................................................................................................................................................................................................. 28 PET/CT and rheumatic diseases: Expanding ........................................................................................................................................................................................................... 28 Pediatric nuclear medicine ............................................................................................................................................................................................................................................................... 32 Liver PET ........................................................................................................................................................................................................................................................................................................ 34 Quantitative Imaging of Liver Functions by PET ............................................................................................................................................................................................................ 34 "Highlights 2016 ....................................................................................................................................................................................................................................................................................... 36 Radionuclide therapy ........................................................................................................................................................................................................................................................................... 43 Neuroendocrine tumours ............................................................................................................................................................................................................................................................ 43 Hepatic malignancies ................................................................................................................................................................................................................................................................... 44 Thyroid disease ................................................................................................................................................................................................................................................................................. 45 Training and teaching .......................................................................................................................................................................................................................................................................... 47 Medical doctors/specialists
Load more

Recommended publications
  • Assessment of Cardiac Amyloidosis with 99MTC- Pyrophosphate (PYP) Quantitative Spect
    Assessment of Cardiac Amyloidosis With 99MTC- pyrophosphate (PYP) Quantitative Spect Chao Ren Peking Union Medical College Hospital Jingyun Ren Peking Union Medical College Hospital Zhuang Tian Peking Union Medical College Hospital Yanrong Du Peking Union Medical College Hospital Zhixin Hao Peking Union Medical College Hospital Zongyao Zhang Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital Wei Fang Chinese Academy of Medical Sciences & Peking Union Medical College Fuwai Hospital Fang Li Peking Union Medical College Hospital Shuyang Zhang Peking Union Medical College Hospital Bailing Hsu University of Missouri-Columbia Li Huo ( [email protected] ) Peking Union Medical College Hospital https://orcid.org/0000-0003-1216-083X Original research Keywords: ATTR cardiomyopathy, 99mTc-PYP quantitative SPECT, standardized uptake value, diagnostic feasibility, the operator reproducibility Posted Date: June 5th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-32649/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/25 Version of Record: A version of this preprint was published on January 7th, 2021. See the published version at https://doi.org/10.1186/s40658-020-00342-7. Page 2/25 Abstract Background: 99mTc-PYP scintigraphy provides differential diagnosis of ATTR cardiomyopathy (ATTR-CM) from lightchain cardiac amyloidosis and other myocardial disorders without biopsy. This study was aimed to assess the diagnostic feasibility and the operator reproducibility of 99mTc-PYP quantitative SPECT. Method:Thirty-seven consecutive patients underwent a99mTc-PYP thorax planar scan followed by SPECT and CT scans to diagnose suspected ATTR-CM were enrolled. For the quantitative SPECT, phantom studies were initially performed to determine the image conversion factor (ICF) and partial volume correction (PVC) factor to recover 99mTc-PYP activity concentration in myocardium for calculating the standardized uptake value (SUV) (unit: g/ml).
    [Show full text]
  • Brain Imaging
    Publications · Brochures Brain Imaging A Technologist’s Guide Produced with the kind Support of Editors Fragoso Costa, Pedro (Oldenburg) Santos, Andrea (Lisbon) Vidovič, Borut (Munich) Contributors Arbizu Lostao, Javier Pagani, Marco Barthel, Henryk Payoux, Pierre Boehm, Torsten Pepe, Giovanna Calapaquí-Terán, Adriana Peștean, Claudiu Delgado-Bolton, Roberto Sabri, Osama Garibotto, Valentina Sočan, Aljaž Grmek, Marko Sousa, Eva Hackett, Elizabeth Testanera, Giorgio Hoffmann, Karl Titus Tiepolt, Solveig Law, Ian van de Giessen, Elsmarieke Lucena, Filipa Vaz, Tânia Morbelli, Silvia Werner, Peter Contents Foreword 4 Introduction 5 Andrea Santos, Pedro Fragoso Costa Chapter 1 Anatomy, Physiology and Pathology 6 Elsmarieke van de Giessen, Silvia Morbelli and Pierre Payoux Chapter 2 Tracers for Brain Imaging 12 Aljaz Socan Chapter 3 SPECT and SPECT/CT in Oncological Brain Imaging (*) 26 Elizabeth C. Hackett Chapter 4 Imaging in Oncological Brain Diseases: PET/CT 33 EANM Giorgio Testanera and Giovanna Pepe Chapter 5 Imaging in Neurological and Vascular Brain Diseases (SPECT and SPECT/CT) 54 Filipa Lucena, Eva Sousa and Tânia F. Vaz Chapter 6 Imaging in Neurological and Vascular Brain Diseases (PET/CT) 72 Ian Law, Valentina Garibotto and Marco Pagani Chapter 7 PET/CT in Radiotherapy Planning of Brain Tumours 92 Roberto Delgado-Bolton, Adriana K. Calapaquí-Terán and Javier Arbizu Chapter 8 PET/MRI for Brain Imaging 100 Peter Werner, Torsten Boehm, Solveig Tiepolt, Henryk Barthel, Karl T. Hoffmann and Osama Sabri Chapter 9 Brain Death 110 Marko Grmek Chapter 10 Health Care in Patients with Neurological Disorders 116 Claudiu Peștean Imprint 126 n accordance with the Austrian Eco-Label for printed matters.
    [Show full text]
  • Vizamyl, INN-Flutemetamol (18F)
    26 June 2014 EMA/546752/2014 Committee for Medicinal Products for Human Use (CHMP) Vizamyl flutemetamol (18F) Procedure No. EMEA/H/C/002553 Marketing authorisation holder: GE HEALTHCARE LIMITED Assessment report for an initial marketing authorisation application Assessment report as adopted by the CHMP with all commercially confidential information deleted 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European Union © European Medicines Agency, 2014. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Manufacturers ...................................................................................................... 8 1.3. Steps taken for the assessment of the product ......................................................... 8 2. Scientific discussion ................................................................................ 9 2.1. Introduction......................................................................................................... 9 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction ...................................................................................................
    [Show full text]
  • Northern Ireland Nuclear Medicine Equipment Survey, 2017
    Northern Ireland nuclear medicine equipment survey 2017 Northern Ireland nuclear medicine equipment survey 2017 About Public Health England Public Health England exists to protect and improve the nation’s health and wellbeing and reduce health inequalities. We do this through world-leading science, knowledge and intelligence, advocacy, partnerships and the delivery of specialist public health services. We are an executive agency of the Department of Health and Social Care, and a distinct delivery organisation with operational autonomy. We provide government, local government, the NHS, Parliament, industry and the public with evidence-based professional, scientific and delivery expertise and support. Public Health England Wellington House 133-155 Waterloo Road London SE1 8UG Tel: 020 7654 8000 www.gov.uk/phe Twitter: @PHE_uk Facebook: www.facebook.com/PublicHealthEngland © Crown copyright 2019 You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v3.0. To view this licence, visit OGL. Where we have identified any third-party copyright information you will need to obtain permission from the copyright holders concerned. Published January 2019 PHE publications PHE supports the UN Sustainable Development Goals 2 Northern Ireland nuclear medicine equipment survey 2017 Contents Executive summary 4 Introduction 5 Methodology 6 Number of procedures performed 7 Procedures per scanner 8 Age of Scanners 9 Procedures reported for each organ or system 10 Procedures reported
    [Show full text]
  • Startboligerne I Aarhus Nord Er Du Mellem 18 Og 24 År Og Har Du Brug for Støtte I Forbindelse Med at Flytte I Egen Lejlighed? Hvad Er Startboliger?
    Startboligerne i Aarhus Nord Er du mellem 18 og 24 år og har du brug for støtte i forbindelse med at flytte i egen lejlighed? Hvad er startboliger? • Startboligerne er for unge mellem 18 og 24 år, som har behov for og interesse i at få en uddannelse eller arbejde, og som har et ønske om at klare sig selv og tage aktivt del i samfundet. • Som beboer i en startbolig skal du selv ønske at modtage hjælp. • Startboligerne i Aarhus Nord administreres af Kollegiekontoret i Aarhus. • I ansøgningsprocessen samarbejder Kollegiekontoret med Aarhus Kommune om at finde beboerne til startboligerne. Hvor ligger startboligerne? Boligerne er beliggende på 6 kollegier i Skejby/Vejlby idet nordlige Aarhus relativt tæt på Aarhus midtby. Boligerne er be- liggende tæt på mange uddannelsesinstitioner, busforbindelser og butikker. Den sociale vicevært Jane Riddermann Christiansen er ansat som social vicevært. Hun har kontor i Skejby Centeret og vil hjælpe med at skabe et godt hjem for dig. Hun kan støtte, vejlede og rådgive dig. Jane kan også hjælpe med at planlægge aktiviteter, som styrker dit netværk og dine sociale, faglige og personlige kompetencer. Du kan søge om startbolig, hvis: □ Du er mellem 18 og 24 år gammel □ Du har svært ved at få og fastholde en bolig □ Du har svært ved at få dagligdagen i egen lejlighed til at fungere (f.eks. tøjvask, indkøb og økonomi) □ Du selv ønsker at modtage hjælp og samarbejde med den sociale vicevært Hvad kan du få hjælp til Vi fokuserer på, at du skal lære at bo for dig selv. Men den sociale vicevært er der for at hjælpe med de ting du har brug for - f.eks.
    [Show full text]
  • October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs
    WWW.SNMMI.ORG Final Rule 2020 Compared to October 2019 Rates Medicare Hospital Outpatient Prospective Payment System HOPPS (APC) Medicine Procedures, Radiopharmaceuticals, and Drugs October 2019 Rates CY 2020 Final Rule Updated April 2, 2020 Status Item/Code/Service OPPS Payment Status Indicator Services furnished to a hospital outpatient that are paid under a fee schedule or Not paid under OPPS. Paid by MACs under a fee schedule or payment system other than OPPS. payment system other than OPPS,* for example: A ● Separately Payable Clinical Diagnostic Laboratory Services (Not subject to Services are subject to deductible or coinsurance unless indicated otherwise. deductible or coinsurance.) D Discontinued Codes Not paid under OPPS or any other Medicare payment system. Items and Services: ● Not covered by any Medicare outpatient benefit category Not paid by Medicare when submitted on outpatient claims (any outpatient bill E1 ● Statutorily excluded by Medicare type). ● Not reasonable and necessary Items and Services: Not paid by Medicare when submitted on outpatient claims (any outpatient bill ● for which pricing information and claims data are not E2 type). available G Pass-Through Drug/ Biologicals Paid under OPPS; separate APC payment NonPass-Through Drugs and nonimplantable Biologicals, including Therapeutic Paid under OPPS; separate APC payment K Radiopharmaceuticals Paid under OPPS; payment is packaged into payment for other services. Items and Services packaged into APC rate N Therefore, there is no separate APC payment. Paid under OPPS; Addendum B displays APC assignments when services are separately payable. (1) Packaged APC payment if billed on the same claim as a HCPCS code STV-Packaged assigned status indicator “S,” “T,” or “V.” Q1 Codes (2) Composite APC payment if billed with specific combinations of services based on OPPS composite-specific payment criteria.
    [Show full text]
  • FDG PET for the Diagnosis of Dementia
    PET for Clinicians Christopher C. Rowe MD FRACP Austin Health University of Melbourne PET in dementia is not new but only in recent years, as PET has become more accessible, has a clinical role emerged. Austin Health, Melbourne does 1000 brain PET per year. Parieto-temporal hypometabolism in AD Clinical Diagnosis of AD • Sensitivity 80%, Specificity 70% (Knopfman, Neurology 2001- average of 13 studies with pathological confirmation) i.e. diagnosis requires dementia and only has moderate accuracy Mild Cognitive Impairment (MCI) does not equate to early AD • Only 50% of MCI will progress to AD dementia • 15-20% have other dementias. • 35-40% do not develop dementia. We need biomarkers for early diagnosis of AD and other dementias! New Research Criteria for AD (2007)* • dementia or significant functional impairment is NOT required • clear history of progressive cognitive decline • objective evidence from psychometric tests of episodic memory impairment • characteristic abnormalities in the CSF or in neuroimaging studies (MRI, FDG-PET, Aβ PET) *Dubois B, Feldman HH, Jacova C, et al. Lancet 2007. FDG PET in Alzheimer’s disease Parietotemporal hypometabolism Reiman EM et al. New Engl J Med 1996;334(12):752–758. View in AC-PC plane bottom of frontal lobe and occipital lobe on same horizontal plane in mid sagittal image Prefrontal Primary sensori-motor cortex Parietal Austin & Repatriation Medical Centre Department of Nuclear Medicine & Centre for PET Reading Brain PET Compare: • parietal vs sensori-motor and frontal • posterior cingulate vs
    [Show full text]
  • SNMMI Fact Sheet Amyloid.Indd
    Amyloid PET Imaging INDICATION: • Amyloid imaging radiopharmaceuticals are indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline. RADIOPHARMACEUTICALS (FDA APPROVED): • 18F-Florbetapir (Amyvid™, Eli Lilly) • 18F-Florbetaben (NeuraCeq™, Piramal Life Sciences) • 18F-Flutemetamol (Vizamyl™, GE Healthcare) CONTRAINDICATIONS: • Inability to cooperate with PET brain imaging. • Amyloid PET imaging should be performed on a pregnant woman only if there is a clear clinical benefi t. • Previous reaction to the radiopharmaceutical or any excipient. ADVERSE REACTIONS (SEE INDIVIDUAL PACKAGE INSERT FOR COMPLETE LISTINGS): • 18-F Florbetapir (Amyvid™) - headache (<2%), dizziness, nausea (<1%), fatigue (<1%), injection site reaction (<1%). • 18F-Florbetaben (NeuraCeq™) - injection site reactions (<2%) consisting of erythema, irritation and pain. • 18F-Flutemetamol (Vizamyl™) - fl ushing (2%), blood pressure increase (2%), headache (1%), nausea (1%), dizziness (1%) STORAGE: • Store radiopharmaceutical at room temperature. • Radiopharmaceutical is provided in unit dose syringe and must not be diluted. PATIENT PREPARATION: • It is not necessary for patients to be NPO prior to imaging. • It is not necessary to control the post injection conditions (e.g. ambient light, temperature, noise). • It is not necessary to discontinue any medications. • Patient should wear comfortable clothing, with no metal on head (hair clips, earrings, etc.) • If patient is breast feeding, recommend discontinuation of breast feeding for 24 hours after administration of radiopharmaceutical. • It is often useful to engage a family member or caregiver in the process of explaining the scan procedure and assessing the patient’s ability to follow instructions.
    [Show full text]
  • Programme for the Phd Day 2010 (Full
    UNIVERSITY OF AARHUS GRADUATE SCHOOL OF HEALTH SCIENCES PhD Day 15 January 2010 2 Welcome It is our pleasure to welcome students, faculty, and guests to the PhD Day 2010. We warmly thank all those who have taken the time to participate and help make the PhD Day a leading event in the training of our graduate students. The world of science is by nature global and to go international is a key ambition of the PhD programme in Denmark. Aarhus Graduate School of Health Sciences acknowledges that internationalisation is a very important aspect of science, not least for the individual PhD student. One way to support internationalisation is by networking. The theme of the PhD Day 2010 is thus INTERNATIONAL NETWORKING. Nine PhD students coming from USA, England, Sweden, Switzerland, and France will spend a day with PhD students from Aarhus. They were invited by the respective Graduate Programmes and we trust that this day of science related as well as social activities will lead to new contacts, further networking and new collaborations across borders. As is evident from the abstracts presented in this programme book the Aarhus Graduate School of Health Sciences provides a vibrant scientific environment ready to meet new challenges and offering many opportunities. The PhD students are central to research and research environments and the Organizing Committee is satisfied that this book shows the commitment and high quality research done at our Faculty. The Organizing Committee and the Faculty of Health Sciences are confident that the PhD Day 2010 will be a success and we cordially welcome all participants.
    [Show full text]
  • The Practice of Internal Dosimetry in Nuclear Medicine
    The Practice of Internal Dosimetry in Nuclear Medicine Series in Medical Physics and Biomedical Engineering Series Editors: John G Webster, E Russell Ritenour, Slavik Tabakov, and Kwan-Hoong Ng Other recent books in the series: Environmental Radioactivity and Emergency Preparedness Mats Isaksson and Christopher L. Rääf Radiation Protection in Medical Imaging and Radiation Oncology Richard J. Vetter and Magdalena S. Stoeva (Eds) Graphics Processing Unit-Based High Performance Computing in Radiation Therapy Xun Jia and Steve B. Jiang (Eds) Statistical Computing in Nuclear Imaging Arkadiusz Sitek The Physiological Measurement Handbook John G Webster (Ed) Radiosensitizers and Radiochemotherapy in the Treatment of Cancer Shirley Lehnert Diagnostic Endoscopy Haishan Zeng (Ed) Medical Equipment Management Keith Willson, Keith Ison, and Slavik Tabakov Targeted Muscle Reinnervation: A Neural Interface for Artificial Limbs Todd A Kuiken; Aimee E Schultz Feuser; Ann K Barlow (Eds) Quantifying Morphology and Physiology of the Human Body Using MRI L Tugan Muftuler (Ed) Monte Carlo Calculations in Nuclear Medicine, Second Edition: Applications in Diagnostic Imaging Michael Ljungberg, Sven-Erik Strand, and Michael A King (Eds) Vibrational Spectroscopy for Tissue Analysis Ihtesham ur Rehman, Zanyar Movasaghi, and Shazza Rehman Webb’s Physics of Medical Imaging, Second Edition M A Flower (Ed) Series in Medical Physics and Biomedical Engineering The Practice of Internal Dosimetry in Nuclear Medicine Michael G. Stabin Vanderbilt University Nashville, Tennessee, USA Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2017 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S.
    [Show full text]
  • Sognegrænser I Vejlby-Risskov
    Sognegrænser i Vejlby-Risskov Ellevang Sogn Mod nord – Fra Mollerup Golfklub i vest, langs Egåen til Grenåvej. Mod øst – Fra Egåen ad Grenåvej (ulige numre) til jernbanen. Langs jernbanens vestside til Forteledet. Mod syd – Langs Forteledet (ulige numre) til Vestre Strandallé. Et lille stykke langs Vestre Strandallé (lige numre). Langs Fortebakken (lige numre) til Skolesvinget. Langs Skolesvinget (ulige numre) til rundkørslen. Langs Skolevangsallé (ulige numre) til Grenåvej. Langs Grenåvej (vestsiden) til Bakkegårdsvej (gamle udmunding i Grenåvej). Langs Bakkegårdsvej (lige numre) til Toftefaldet. Langs Toftefaldet (ulige numre) til Nordlandsvej. Langs Nordlandsvej (vestsiden) til Kildehøjen. Langs Kildehøjen (lige numre) til Tværmarksvej. Langs Tværmarksvej (lige numre) til Langengevej. Mod vest – Langs Langengevej (lige numre) til Skejby Nordlandsvej. Langs Langengevej på den anden side af Skejby Nordlandsvej. Langs Langendevej (nordsiden) mod vest indtil den bliver til Mollerupvej. Langs Mollerupvej (østsiden) til golfbanen. Gennem den østlige del golfbanen til Egåen. Vejlby Sogn Mod Nord – Nordsiden af Langengevej (på den nordre side af Skejby Nordlandsvej) fra Mollerupvej. Langs Langengevej (ulige numre) til Tværmarksvej. Langs Tværmarksvej (ulige numre) til Kildehøjen. Langs Kildehøjen (ulige numre) til Nordlandsvej. Langs Nordlandsvej (østsiden) til Toftefaldet. Langs Toftefaldet (lige numre) til Bakkegårdsvej. Langs Bakkegårdsvej (ulige nure) til Grenåvej (den gamle udmunding). Langs Grenåvej (vestsiden) til Skolevangsallé. Mod øst – Langs Skolevangsallé (life numre) til rundkørslen. Langs Skovagervej (ulige numre) til Bækkelundsvej. Langs Bækkelundsvej (mod vest – ulige numre) til Tretommervej. Langs Tretommervej (ulige numre) til rundkørslen. Langs Asylvej (ulige numre) til Vestre Skovvej. Langs Vestre Skovvej (ulige numre) til Risskoven. Langs Risskoven (langs sydsiden af Risskov Haveforening). Mod syd – Langs Risskoven (langs sydsiden af Risskov Haveforening).
    [Show full text]
  • Vejlby Kirke Hasle Herred
    Fig. 1. Vejlby. Kirken set fra øst. - The church seen from east. K.deF. L. 1963 VEJLBY KIRKE HASLE HERRED ejlby kirke hørte i middelalderen under kantorembedet ved domkirken i Århus1. 26. april 1687 V overdrog kongen kirken til kirkeskriverembedet2, og 29. april 1720 skødede han den til købmand Jens Andersen Møller i Århus3. Efter dennes død 1741 arvedes kirken af datteren Maren Jensdatter Møller, der var enke efter byfoged Oluf Andersen4 (jfr. oversigten, p. 1468). Maren Møller døde 1766, og hendes søstersøn og universalarving Magnus von Beringskjold afstod ved skøde af 11. december 1770 kirken til amtsforvalter Jens Thygesen5, som året efter skødede den til Ole Christian Secher6. På auktion 31. juli 1777 solgte denne kirken til Lars Madsen Perstrup i Gråmølle7, der 15. december 1784 solgte den til Anders Rasmussen i Brendstrup og Christian Faurschou i Århus8 (jfr. †alterklæde). 1810 afhændede Christian og Anders Faurschou kirketienden til sognets hartkornbesiddere9. Kantor ved domkapillet i Århus, i hvis beneficium Vejlby kirke som nævnt var inkorporeret, lod sognet betjene af forskellige, ordinerede personer, sidst af en mand, der Danmarks Kirker, Århus amt 93 1454 HASLE HERRED Fig. 2. Vejlby. Kirken set fra nordøst. The church seen from north-east. K.deF.L.1988 tillige var rektor for latinskolen. l680 døde den sidste kantor, og det følgende år blev sognet annekteret øverste kapellani ved domkirken (jfr. †præsterække). Reskript af 26. angust 1803 bestemte, at Vejlby sogn ved næste vakance skulle udgøre et selvstændigt præstekald. Denne ledighed indtraf 1811, da C.V. Hertel, der kendes som Århus domkirkes historiograf, og som har givet en indgående skildring af Vejlby sogn og kirke, søgte væk og fik embede i Øster Tørslev.
    [Show full text]